Evidence based strategies for secondary prevention of ischaemic heart disease: Time to improve clinical practice

New Zealand Medical Journal

Volumn 111, Issue 1065, 1998, Pages 170-172

  Ellis, C J ^a   O'Meeghan, T ^b   Hamer, A W ^c   Gordon, G D ^a   Patel, H ^d  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b Invercargill Hospital   (New Zealand)

^c NELSON HOSPITAL   (New Zealand)

^d TAURANGA HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEVINOLIN; PRAVASTATIN; TRANDOLAPRIL;

ALCOHOL CONSUMPTION; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY RISK; DRUG EFFICACY; ESTROGEN THERAPY; EXERCISE; HUMAN; ISCHEMIC HEART DISEASE; OBESITY; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; RISK MANAGEMENT; SECONDARY PREVENTION; SMOKING CESSATION; WEIGHT REDUCTION;

CORONARY DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 0032496383     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Hay DR Cardiovascular disease in New Zealand, 1996: a summary of recent statistical information. The National Heart Foundation of New Zealand: Technical Report No. 70; October 1996.
2. Jackson R, Beaglehole R. Trends in dietary fat and cigarette smoking and the decline in coronary heart disease in New Zealand. Int J Epidemiol 1987; 16: 377-82.
3. Beaglehole R, Jackson R, Stewart A. Diet, serum cholesterol and the prevention of coronary heart disease in New Zealand. NZ Med J 1988; 101: 415-8.
4. Fibrinolytic Therapy Trialists' Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
5. Ellis CJ, French JK, White HD. Coronary arterial patency and survival in clinical trials. J Thrombosis Thrombolysis 1997; 4: 239-50.
6. Neutze JM, White HD. What contribution has cardiac surgery made to the decline in mortality from coronary heart disease? BMJ 1987; 294: 405-9.
7. Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists' Collaboration. Lancet 1994; 344: 563-70.
8. Hunink MG, Goldman L, Tosteston AN et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-42.
9. The ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events), Heart 1996; 75: 334-42.
10. Ellis CJ, French JK, White HD et al. Good medium-term outcome following percutaneous coronary angioplasty in young patients. Circulation 1996; 94 suppl 1:1-59.
11. Shaper AG, Pocock SJ, Walker M et al. Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health. 1985; 39: 197-209.
12. Hubert HB, Holford TR, Kannel WB. Clinical characteristics and cigarette smoking in relation to prognosis of angina pectoris in Framingham. Am J Epidemiol 1982; 115: 231-42.
13. Daly LE, Graham IM, Hickey N, Mulcahy R. Does stopping smoking delay onset of angina after infarction? BMJ 1985; 291: 935-7.
14. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial infarction: diet and Reinfarction Trial (DART). Lancet 1989; 2: 757-61.
15. Singh RB, Rastogi SS, Verma R et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992; 304:1015-9.
16. National Cholesterol Education Programme. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II. Circulation 1994; 89: 1329-445.
17. O'Connor GT, Buring JE, Yusuf S et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234-44.
18. Arroll B, Swinburn B, Russell D, Lubbe WF. Physical activity and heart disease. The National Heart Foundation of New Zealand, Technical Report No. 63; May 1994.
19. Pyorala K, De Backer G, Graham I et al. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31.
20. Wong ND, Cupples LA, Ostfield AM et al. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Amer J Epidemiol 1989; 130: 469-80.
21. Poulter N. Cardiovascular disease: risk factors and interventions. Oxford: Radcliffe Medical Press; 1993. p 49-50.
22. Friedman GD, Klatsky AL. Is alcohol good for your health? [Editorial] N Engl J Med 1993; 329: 1882-3.
23. Gaziano JM, Buring JE, Breslow JL et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its s infractions, and decreased risk of myocardial infarction. N Engl J Med 1993; 329: 1829-34.
24. Stampfer MJ, Hennekens CH, Manson JE et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9.
25. Rimm EG, Stampfer MJ, Ascheno A et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6.
26. Stephens NG, Parsons A, Schiafelli PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
27. Rapola J, Virtamo J, Ripatti S et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715-20.
28. HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of large, simple randomised trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE Study Investigators. Can J Cardiol 1996; 12: 127-37.
29. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of anti-platelet therapy -1: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
30. Ellis CJ, White HD. New anti-platelet strategies in the adjunctive treatment of acute myocardial infarction. In: Becker R, editor. Textbook of coronary thrombosis and thrombolysis. Massachusetts: Kluwer Academic Publishers: 1997. p375-87.
31. Yusuf S, Peto R, Lewis J et al. Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27: 335-71.
32. Pederson TR, for the Norwegian Multicenter Study Group. Six-year follow up of the Norwegian Multicenter Study on timolol after acute myocardial infarction. N Engl J Med 1985; 313: 1055-8.
33. Yusuf S, Lessen J, Jahn P, Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials. J Hypertens 1993; 11 Suppl: 561-73.
34. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (4S). Lancet 1994; 344: 1383-9.
35. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
36. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1979; 231: 360-81.
37. Ericsson C, Hamsten A, Nilsson J et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53.
38. Dyslipidaemia Advisory Group on behalf of the Scientific Committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation Guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996; 109: 224-32.
39. Pharmaceutical Management Agency Ltd (PHARMAC). New Zealand Pharmaceutical Schedule. Wellington; December 1996.
40. Patel H, Neutze JM, Kerr B, White HD. Failure of the implementation of the National Heart Foundation of New Zealand guidelines for the management of dyslipidaemia. NZ Med J 1996; 109: 24-6.
41. Pharmaceutical Management Agency Ltd (PHARMAC). New Zealand Pharmaceutical Schedule. Wellington; August 1997.
42. Ellis C, McHaffie D, Elliott J, Wilkins G. Statins and Pharmac [letter]. NZ Med J 1998; 111: 38.
43. Ose L, Scott R. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. Clin Drug Invest 1995; 10: 127-38.
44. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA Reductase Inhibitors. Clin Ther 1994; 16: 366-85.
45. Pfeffer MA, Braumwold E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med 1992; 327: 669-77.
46. GISSI-3: effects of lisinopril and transdermal glycerl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
47. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
48. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
49. Yusuf S, Pepine CJ, Carces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8.
50. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
51. ASPECT Research Group. Effect of long-term oral anticoagulation treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499-503.
52. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med 1992; 117: 1016-37.
53. Hamer AW, White HD. Women and coronary heart disease. NZ Med J 1993; 106: 176-7.
54. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995; 273: 199-208.
55. Grodstein F, Stampfer MJ, Colditz GA et al. Postmenopausal hormone replacement therapy and mortality. N Engl J Med 1997; 336: 1769-75.
56. Healy B. PEPI in perspective: Good answers spawn pressing questions. JAMA 1995; 273:240-1.
57. Andrade SF, Walker AM, Gottlieb KL et al. Discontinuation of antihypertemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31.
58. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996, 164: 208-11.